Patheon Inc. signs two 5-year manufacturing agreement renewals with Sanofi-Aventis

Jan 11, 2010, 08:00 ET from Patheon Inc.

Agreements extend long standing manufacturing partnership between the companies

TORONTO, Jan. 11 /PRNewswire-FirstCall/ - Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it has signed two 5-year manufacturing agreements with Sanofi-Aventis. These agreements, for products manufactured in Patheon's Swindon and Bourgoin facilities, extend the company's longstanding partnership with Sanofi-Aventis to provide high quality outsourced manufacturing services.

Wes Wheeler, Chief Executive Officer and President of Patheon Inc. said, "We are very pleased with the partnership we have developed with Sanofi-Aventis over the past 10 years. The agreements mark another milestone in our relationship which was initiated through site acquisition and enables our mission to offer world-class facilities and expertise, with an unwavering focus on service quality."

ABOUT PATHEON

Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of 11 facilities and eight development centers, across North America and Europe, strives to ensure that customer products can be launched timely and confidently anywhere in the world.

SOURCE Patheon Inc.